DANONE (BSN.DE) Fundamental Analysis & Valuation

FRA:BSNFR0000120644

Current stock price

67.5 EUR
-0.4 (-0.59%)
Last:

This BSN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BSN.DE Profitability Analysis

1.1 Basic Checks

  • BSN had positive earnings in the past year.
  • BSN had a positive operating cash flow in the past year.
  • Each year in the past 5 years BSN has been profitable.
  • Each year in the past 5 years BSN had a positive operating cash flow.
BSN.DE Yearly Net Income VS EBIT VS OCF VS FCFBSN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 4.03%, BSN is in line with its industry, outperforming 55.17% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 10.73%, BSN is in line with its industry, outperforming 58.62% of the companies in the same industry.
  • BSN has a better Return On Invested Capital (7.75%) than 63.79% of its industry peers.
  • BSN had an Average Return On Invested Capital over the past 3 years of 7.51%. This is in line with the industry average of 7.16%.
  • The 3 year average ROIC (7.51%) for BSN is below the current ROIC(7.75%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.03%
ROE 10.73%
ROIC 7.75%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
BSN.DE Yearly ROA, ROE, ROICBSN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • Looking at the Profit Margin, with a value of 6.66%, BSN is in the better half of the industry, outperforming 62.07% of the companies in the same industry.
  • BSN's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 13.43%, BSN belongs to the top of the industry, outperforming 86.21% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BSN has remained more or less at the same level.
  • The Gross Margin of BSN (50.62%) is better than 82.76% of its industry peers.
  • BSN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
BSN.DE Yearly Profit, Operating, Gross MarginsBSN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

4

2. BSN.DE Health Analysis

2.1 Basic Checks

  • BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, BSN has less shares outstanding
  • The number of shares outstanding for BSN has been reduced compared to 5 years ago.
  • Compared to 1 year ago, BSN has a worse debt to assets ratio.
BSN.DE Yearly Shares OutstandingBSN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BSN.DE Yearly Total Debt VS Total AssetsBSN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 2.37 indicates that BSN is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of BSN (2.37) is better than 62.07% of its industry peers.
  • The Debt to FCF ratio of BSN is 5.29, which is a neutral value as it means it would take BSN, 5.29 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 5.29, BSN is doing good in the industry, outperforming 67.24% of the companies in the same industry.
  • A Debt/Equity ratio of 0.73 indicates that BSN is somewhat dependend on debt financing.
  • BSN has a Debt to Equity ratio of 0.73. This is in the lower half of the industry: BSN underperforms 60.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 5.29
Altman-Z 2.37
ROIC/WACC1.22
WACC6.33%
BSN.DE Yearly LT Debt VS Equity VS FCFBSN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • BSN has a Current Ratio of 0.90. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.90, BSN is not doing good in the industry: 79.31% of the companies in the same industry are doing better.
  • BSN has a Quick Ratio of 0.90. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BSN has a Quick ratio (0.75) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.75
BSN.DE Yearly Current Assets VS Current LiabilitesBSN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

4

3. BSN.DE Growth Analysis

3.1 Past

  • BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.68%.
  • BSN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.61% yearly.
  • BSN shows a decrease in Revenue. In the last year, the revenue decreased by -0.34%.
  • The Revenue has been growing slightly by 2.93% on average over the past years.
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%

3.2 Future

  • Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 7.81% on average per year.
  • The Revenue is expected to grow by 4.25% on average over the next years.
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.81%
Revenue Next Year2.57%
Revenue Next 2Y3.27%
Revenue Next 3Y3.55%
Revenue Next 5Y4.25%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BSN.DE Yearly Revenue VS EstimatesBSN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
BSN.DE Yearly EPS VS EstimatesBSN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4 5

4

4. BSN.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 17.76, the valuation of BSN can be described as rather expensive.
  • The rest of the industry has a similar Price/Earnings ratio as BSN.
  • BSN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.53.
  • The Price/Forward Earnings ratio is 16.67, which indicates a correct valuation of BSN.
  • BSN's Price/Forward Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 37.95, BSN is valued rather cheaply.
Industry RankSector Rank
PE 17.76
Fwd PE 16.67
BSN.DE Price Earnings VS Forward Price EarningsBSN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSN is on the same level as its industry peers.
  • Based on the Price/Free Cash Flow ratio, BSN is valued a bit cheaper than the industry average as 67.24% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 16.88
EV/EBITDA 9.35
BSN.DE Per share dataBSN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.71
PEG (5Y)6.79
EPS Next 2Y6.99%
EPS Next 3Y7.19%

6

5. BSN.DE Dividend Analysis

5.1 Amount

  • BSN has a Yearly Dividend Yield of 3.28%.
  • Compared to an average industry Dividend Yield of 2.60, BSN pays a bit more dividend than its industry peers.
  • BSN's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 3.28%

5.2 History

  • The dividend of BSN has a limited annual growth rate of 0.46%.
Dividend Growth(5Y)0.46%
Div Incr Years4
Div Non Decr Years5
BSN.DE Yearly Dividends per shareBSN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • BSN pays out 75.94% of its income as dividend. This is not a sustainable payout ratio.
  • BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP75.94%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
BSN.DE Yearly Income VS Free CF VS DividendBSN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
BSN.DE Dividend Payout.BSN.DE Dividend Payout, showing the Payout Ratio.BSN.DE Dividend Payout.PayoutRetained Earnings

BSN.DE Fundamentals: All Metrics, Ratios and Statistics

DANONE

FRA:BSN (4/16/2026, 7:00:00 PM)

67.5

-0.4 (-0.59%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-20
Earnings (Next)04-22
Inst Owners55.19%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap45.99B
Revenue(TTM)27.28B
Net Income(TTM)1.82B
Analysts75.76
Price Target81.41 (20.61%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.28%
Yearly Dividend2.15
Dividend Growth(5Y)0.46%
DP75.94%
Div Incr Years4
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.79%
PT rev (3m)0.69%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.89%
EPS NY rev (3m)-3.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.84%
Valuation
Industry RankSector Rank
PE 17.76
Fwd PE 16.67
P/S 1.69
P/FCF 16.88
P/OCF 12.17
P/B 2.72
P/tB N/A
EV/EBITDA 9.35
EPS(TTM)3.8
EY5.63%
EPS(NY)4.05
Fwd EY6%
FCF(TTM)4
FCFY5.92%
OCF(TTM)5.55
OCFY8.22%
SpS40.04
BVpS24.83
TBVpS-9.13
PEG (NY)2.71
PEG (5Y)6.79
Graham Number46.0744 (-31.74%)
Profitability
Industry RankSector Rank
ROA 4.03%
ROE 10.73%
ROCE 12.04%
ROIC 7.75%
ROICexc 9.68%
ROICexgc 76.66%
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
FCFM 9.99%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.51%
ROIC(5y)7.21%
ROICexc(3y)9.24%
ROICexc(5y)8.74%
ROICexgc(3y)70.2%
ROICexgc(5y)59.95%
ROCE(3y)11.59%
ROCE(5y)10.94%
ROICexgc growth 3Y20.15%
ROICexgc growth 5Y16.9%
ROICexc growth 3Y6.6%
ROICexc growth 5Y4.3%
OM growth 3Y3.21%
OM growth 5Y-0.93%
PM growth 3Y24.9%
PM growth 5Y-4.13%
GM growth 3Y3.2%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.73
Debt/FCF 5.29
Debt/EBITDA 2.46
Cap/Depr 77.86%
Cap/Sales 3.87%
Interest Coverage 21.06
Cash Conversion 75.3%
Profit Quality 150.06%
Current Ratio 0.9
Quick Ratio 0.75
Altman-Z 2.37
F-Score7
WACC6.33%
ROIC/WACC1.22
Cap/Depr(3y)69.82%
Cap/Depr(5y)67.75%
Cap/Sales(3y)3.44%
Cap/Sales(5y)3.55%
Profit Quality(3y)197.16%
Profit Quality(5y)188.14%
High Growth Momentum
Growth
EPS 1Y (TTM)4.68%
EPS 3Y3.47%
EPS 5Y2.61%
EPS Q2Q%3.28%
EPS Next Y6.56%
EPS Next 2Y6.99%
EPS Next 3Y7.19%
EPS Next 5Y7.81%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y-0.46%
Revenue growth 5Y2.93%
Sales Q2Q%-0.54%
Revenue Next Year2.57%
Revenue Next 2Y3.27%
Revenue Next 3Y3.55%
Revenue Next 5Y4.25%
EBIT growth 1Y3.01%
EBIT growth 3Y2.73%
EBIT growth 5Y1.96%
EBIT Next Year36.46%
EBIT Next 3Y14.84%
EBIT Next 5Y11.54%
FCF growth 1Y-6.26%
FCF growth 3Y9.25%
FCF growth 5Y6.33%
OCF growth 1Y-1.31%
OCF growth 3Y8.46%
OCF growth 5Y4.96%

DANONE / BSN.DE Fundamental Analysis FAQ

What is the fundamental rating for BSN stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.


What is the valuation status for BSN stock?

ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for DANONE?

DANONE (BSN.DE) has a profitability rating of 7 / 10.


What is the financial health of DANONE (BSN.DE) stock?

The financial health rating of DANONE (BSN.DE) is 4 / 10.


Can you provide the dividend sustainability for BSN stock?

The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 75.94%.